CLOUDR GROUP LTD.
ClouDr Group Limited provides supplies and software as a service (SaaS) installation to hospitals and pharmacies, digital marketing services to pharmaceutical companies, and online consultation and prescriptions for patients with chronic condition management. The company's integrated in-hospital solution offers an AI-driven extensive hospital SaaS to assist doctors in diagnosis and treatment, and… Read more
CLOUDR GROUP LTD. (H3L) - Net Assets
Latest net assets as of : €- EUR
Based on the latest financial reports, CLOUDR GROUP LTD. (H3L) has net assets worth €- EUR as of .
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (€-) and total liabilities (€-). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | €- |
| % of Total Assets | 0% |
| Annual Growth Rate | N/A |
| 5-Year Change | N/A |
| 10-Year Change | N/A |
| Growth Volatility | N/A |
CLOUDR GROUP LTD. - Net Assets Trend (None–None)
This chart illustrates how CLOUDR GROUP LTD.'s net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for CLOUDR GROUP LTD. (None–None)
The table below shows the annual net assets of CLOUDR GROUP LTD. from None to None.
| Year | Net Assets | Change |
|---|---|---|
| No yearly data available. | ||
Equity Component Analysis
This analysis shows how different components contribute to CLOUDR GROUP LTD.'s total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- No equity composition insights available.
CLOUDR GROUP LTD. Competitors by Market Cap
The table below lists competitors of CLOUDR GROUP LTD. ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Dolat Algotech Limited
NSE:DOLATALGO
|
$37.93 Million |
|
Hong Yi Fiber Industry Co Ltd
TW:1452
|
$37.94 Million |
|
Woorison F&G Co. Ltd
KQ:073560
|
$37.94 Million |
|
Laxmi Goldorna House Ltd
NSE:LGHL
|
$37.95 Million |
|
WTK Holdings Bhd
KLSE:4243
|
$37.91 Million |
|
RSUPPORT Co. Ltd
KQ:131370
|
$37.90 Million |
|
GPT Healthcare Ltd
NSE:GPTHEALTH
|
$37.86 Million |
|
NatureCell Co.Ltd
KQ:007390
|
$37.82 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in CLOUDR GROUP LTD.'s equity between the two most recent reporting periods.
Insufficient data available to analyze equity growth attribution.
Book Value vs Market Value Analysis
This analysis compares CLOUDR GROUP LTD.'s book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Insufficient data available to analyze book value vs market value.
Capital Efficiency Dashboard
This dashboard shows how efficiently CLOUDR GROUP LTD. utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Insufficient data available to analyze capital efficiency metrics.
Industry Comparison
This section compares CLOUDR GROUP LTD.'s net assets metrics with peer companies in the Medical Distribution industry.
Industry Context
- Industry: Medical Distribution
- Average net assets among peers: $1,192,244,105,699
- Average return on equity (ROE) among peers: -83.41%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| CLOUDR GROUP LTD. (H3L) | €- | N/A | N/A | $37.91 Million |
| KIMIA FARMA -B- (HQP) | $5.89 Trillion | 5.13% | 1.93x | $78.59 Million |
| Asker Healthcare Group AB (I88) | $3.50 Billion | 10.28% | 2.75x | $1.37 Billion |
| Paragon Care Limited (PXS) | $18.21 Million | 5.96% | 0.48x | $52.86 Million |
| TELES Informationstechnologien AG (TLIK) | $379.23K | -446.97% | 3.69x | $801.14K |
| Sinopharm Group Co. Ltd (X2S) | $68.28 Billion | 8.55% | 2.45x | $3.27 Billion |